OncoCyte Corp Announces Completion Of Determadx™ Clinical Validation Study Transcript
Greetings, and welcome to the OncoCyte Corporation DetermaDx Results Call. (Operator Instructions) As a reminder, this conference is being recorded.
I'll now turn the conference over to our host, Bob Yedid from Investor Relations. Thank you. You may begin.
Thank you, Diego, and thank you, everyone, for joining us for today's conference call to discuss OncoCyte's DetermaDx Clinical Validation Study results. If you have not seen today's press release, please visit OncoCyte's website at www.oncocyte.com.
Before turning the call over to Ronnie Andrews, OncoCyte's President and Chief Executive Officer, I would like to remind you that this conference call -- that during this conference call, the company will make projections and forward-looking statements regarding future events. Any statements that are not historical facts, including, but not limited to, statements that contain words such as will, believe, plans, anticipates, expects,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |